Mangafodipir
drugOn this page
Also known as mn-dpdp
Summary
Mangafodipir (CHEMBL1201301) is an approved small molecule (ATC V08CA05); indicated across 4 conditions including myocardial infarction and colonic neoplasm.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: V08CA05
- Indications: 4 conditions
- Clinical trials: 5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201301 |
| Name | Mangafodipir |
| Type | Small molecule |
| Max phase | 4 |
| ATC | V08CA05 |
Also known as: Mangafodipir, mn-dpdp, MANGAFODIPIR
Parent form; salt/anhydrous children: CHEMBL2096651, CHEMBL5308448
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| myocardial infarction | 2 | MONDO:0005068 | EFO:0000612 |
| colonic neoplasm | 2 | MONDO:0005401 | MONDO:0021063 |
| neoplasm | 2 | MONDO:0005070 | MONDO:0004992 |
| epilepsy | 1 | MONDO:0005027 | EFO:0000474 |
Clinical trials
Total trials: 5.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 3 |
| PHASE1 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00671996 | PHASE2 | COMPLETED | Mangafodipir as an Adjunct to FOLFOX6 Chemotherapy in Colon Cancer Stage Dukes’ C |
| NCT00727922 | PHASE2 | COMPLETED | Protective Effect of Mangafodipir Against Oxaliplatin Neurotoxicity |
| NCT00966563 | PHASE2 | COMPLETED | Mangafodipir as an Adjunct to Percutaneous Coronary Intervention |
| NCT02531880 | PHASE1 | RECRUITING | Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy |
| NCT01326715 | PHASE1 | COMPLETED | Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.